Cerezo Manuela, Laorden M Luisa, Milanés M Victoria
Department of Pharmacology, Equip of Cellular and Molecular Pharmacology, University School of Medicine, Campus de Espinardo, 30100 Murcia, Spain.
Eur J Pharmacol. 2002 Sep 27;452(1):57-66. doi: 10.1016/s0014-2999(02)02245-8.
Our previous studies have shown an enhanced activity of the hypothalamus-pituitary-adrenocortical axis response in rats withdrawn from morphine, which results from an increase in the hypothalamic paraventricular nucleus noradrenergic activity that is dependent on alpha-adrenoceptor activation. The first objective of this work was to examine the effect of protein kinase A (PKA) and protein kinase C (PKC) inhibitors on morphine withdrawal-induced changes in corticosterone release (an index of the hypothalamus-pituitary-adrenocortical axis activity) and in catecholaminergic turnover in the paraventricular nucleus. Plasma corticosterone levels as well as the concentration of noradrenaline, 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) in the paraventricular nucleus were determined. The second purpose of the study was to assess whether kinase inhibitors, administered continuously through s.c. osmotic minipumps, get into the brain. Chronic pretreatment for 7 days with the selective PKA inhibitor N-(2'guanidinoethyl)-5-isoquinolinesulfonamide (HA-1004) concomitantly with morphine did not affect the increase in corticosterone release observed after naloxone-precipitated morphine withdrawal. However, pretreatment with the selective PKC inhibitor, calphostin-C significantly antagonized the corticosterone hypersecretion in morphine-withdrawn rats. Neither HA-1004 nor calphostin-C co-administered with morphine for 7 days did modify the morphine withdrawal-induced increase in noradrenaline turnover. Pretreatment with HA-1004 inhibits the increase in dopamine turnover during morphine withdrawal, whereas calphostin-C did not affect the DOPAC/dopamine ratio. Our results might indicate that expression of morphine dependence for hypothalamus-pituitary-adrenocortical axis hyperactivity involves PKC but not PKA signaling mechanisms. It is suggested that in rats PKC may be up-regulated during morphine dependence. High-performance liquid chromatography (HPLC) analysis of hypothalamic tissue from rats perfused with kinase inhibitors demonstrates that both calphostin-C and HA-1004 can cross the blood-brain barrier when administered peripherally.
我们之前的研究表明,吗啡戒断的大鼠下丘脑-垂体-肾上腺皮质轴反应活性增强,这是由于下丘脑室旁核去甲肾上腺素能活性增加所致,该活性依赖于α-肾上腺素受体激活。本研究的首要目的是检测蛋白激酶A(PKA)和蛋白激酶C(PKC)抑制剂对吗啡戒断诱导的皮质酮释放变化(下丘脑-垂体-肾上腺皮质轴活性指标)以及室旁核儿茶酚胺能代谢的影响。测定了血浆皮质酮水平以及室旁核中去甲肾上腺素、3-甲氧基-4-羟基苯乙二醇(MHPG)、多巴胺和3,4-二羟基苯乙酸(DOPAC)的浓度。本研究的第二个目的是评估通过皮下渗透微型泵持续给药的激酶抑制剂是否能进入大脑。与吗啡同时使用选择性PKA抑制剂N-(2'-胍基乙基)-5-异喹啉磺酰胺(HA-1004)进行7天的慢性预处理,并未影响纳洛酮诱发吗啡戒断后观察到的皮质酮释放增加。然而,用选择性PKC抑制剂钙泊三醇-C预处理可显著拮抗吗啡戒断大鼠的皮质酮分泌过多。与吗啡共同给药7天的HA-1004和钙泊三醇-C均未改变吗啡戒断诱导的去甲肾上腺素代谢增加。用HA-1004预处理可抑制吗啡戒断期间多巴胺代谢的增加,而钙泊三醇-C不影响DOPAC/多巴胺比值。我们的结果可能表明,吗啡依赖对下丘脑-垂体-肾上腺皮质轴功能亢进的表达涉及PKC而非PKA信号机制。提示在大鼠中,PKC可能在吗啡依赖期间上调。对灌注激酶抑制剂的大鼠下丘脑组织进行高效液相色谱(HPLC)分析表明,外周给药时,钙泊三醇-C和HA-1004均可穿过血脑屏障。